Correlation between asymptomatic erosive esophagitis and colorectal polyps

doi:10.16138/j.1673-6087.2022.03.011

Abstract

Abstract:

Objective To explore the correlation between asymptomatic erosive esophagitis(AEE) and colorectal polyps. Methods In this case-control study, the individuals without gastroesophageal reflux symptoms who underwent esophagogastroduodenoscopy(EGD) and colonoscopy in our hospital for a routine health checkup were included in the study and divided into two groups. The AEE group consisted of the patients with erosive esophagitis and without gastroesophageal reflux symptoms. The control group consisted of age-and gender-matched(1∶3) individuals with neither gastroesophageal reflux symptoms nor endoscopic erosive esophagitis. The results of demographics, gastroscopy, colonoscopy, and histopathology were collected. Results A total of 1 176 patients were included in the study, including 294 cases in AEE group and 882 cases in control group. Compared with the control group, the AEE group was more likely to have colorectal polyps(P<0.001), which were mainly distributed in left colon(P<0.001); and the AEE group was more likely to develop high-risk adenomas(P=0.034). In addition, compared with mild AEE, moderate to severe AEE was more possibly to develop high-risk adenomas (P=0.003) and multiple polyps (P<0.001), and the polyps were mainly distributed in left colon(P=0.038). Conclusions The AEE patients are more likely to have polyps, which are mainly distributed in left colon. The moderate to severe AEE patients are more possibly to have high-risk adenomas.

Key words: Esophagitis, Colonic polyps, Adenomas, High-risk adenomas, Gastroesophageal reflux disease

CLC Number:

R571
R574.6

SUN Chao, HUANG Jia, ZHU Ying, YAO Weiyan, TANG Yuming. Correlation between asymptomatic erosive esophagitis and colorectal polyps[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(03): 233-237.

Figures/Tables 4

References 22

[1]	Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus[J]. Am J Gastroenterol, 2006, 101(8): 1900-1920. doi: 10.1111/j.1572-0241.2006.00630.x URL
[2]	Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease[J]. Gastroenterology, 2018, 154(2): 267-276. doi: S0016-5085(17)35977-2 pmid: 28780072
[3]	Lee SP, Sung IK, Kim JH, et al. The clinical features and predisposing factors of asymptomatic erosive esophagitis[J]. Dig Dis Sci, 2016, 61(12): 3522-3529. doi: 10.1007/s10620-016-4341-9 URL
[4]	Takedomi H, Tsuruoka N, Takamori A, et al. Correlation of Barrett’s esophagus with colorectal polyps in Japanese patients: a retrospective chart review[J]. J Gastroenterol Hepatol, 2019, 34(7): 1160-1165. doi: 10.1111/jgh.14610 URL
[5]	Sonnenberg A, Turner KO, Genta RM. Increased risk for colon polyps in patients with reflux disease[J]. Dig Dis Sci, 2018, 63(1): 228-233. doi: 10.1007/s10620-017-4841-2 URL
[6]	Shen J, Wu YL, Mo M, et al. Risk factors associated with early-onset colorectal neoplasm in Chinese youth[J]. Front Oncol, 2021, 11: 702322. doi: 10.3389/fonc.2021.702322 URL
[7]	Souza RF. Reflux esophagitis and its role in the pathogenesis of Barrett’s metaplasia[J]. J Gastroenterol, 2017, 52(7): 767-776. doi: 10.1007/s00535-017-1342-1 URL
[8]	胡志伟, 汪忠镐, 吴继敏, 等. 反流性食管炎严重程度与高分辨率测压的食管动力学关系[J]. 中华医学杂志, 2017, 97(42): 3306-3311.
[9]	Piqué N, Ponce M, Garrigues V, et al. Prevalence of severe esophagitis in Spain. Results of the PRESS study (prevalence and risk factors for esophagitis in Spain)[J]. United European Gastroenterol J, 2016, 4(2): 229-235. doi: 10.1177/2050640615595916 URL
[10]	Shaukat A, Kahi CJ, Burke CA, et al. ACG clinical guidelines: colorectal cancer screening 2021[J]. Am J Gastroenterol, 2021, 116(3): 458-479. doi: 10.14309/ajg.0000000000001122 pmid: 33657038
[11]	Hassan C, Quintero E, Dumonceau JM, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) guideline[J]. Endoscopy, 2013, 45(10): 842-851. doi: 10.1055/s-0033-1344548 URL
[12]	Glebov OK, Rodriguez LM, Nakahara K, et al. Distinguishing right from left colon by the pattern of gene expression[J]. Cancer Epidemiol Biomarkers Prev, 2003, 12(8): 755-762.
[13]	Kasyap AK, Sah SK, Chaudhary S. Clinical spectrum and risk factors associated with asymptomatic erosive esophagitis as determined by Los Angeles classification[J]. PLoS One, 2018, 13(2): e0192739. doi: 10.1371/journal.pone.0192739 URL
[14]	Wu H, Zhang J, Zhou B. Metabolic syndrome and colorectal adenoma risk: a systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2021, 45(5): 101749. doi: 10.1016/j.clinre.2021.101749 URL
[15]	Yuan X, Chen RM, Zhang Y, et al. Gut microbiota of Chinese obese children and adolescents with and without insulin resistance[J].Front Endocrinol (Lausanne), 2021, 12: 636272. doi: 10.3389/fendo.2021.636272 URL
[16]	孙超, 姚玮艳, 黄佳, 等. 无症状糜烂性食管炎的危险因素分析[J]. 内科理论与实践, 2021, 16(3): 188-192.
[17]	McQuaid KR, Laine L, Fennerty MB, et al. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia[J]. Aliment Pharmacol Ther, 2011, 34(2): 146-165. doi: 10.1111/j.1365-2036.2011.04709.x URL
[18]	Okuno K, Nakagawa M, Kojima K, et al. Long-term functional outcomes of Roux-en-Y versus Billroth Ⅰ reconstructions after laparoscopic distal gastrectomy for gastric cancer: a propensity-score matching analysis[J]. Surg Endosc, 2018, 32(11): 4465-4471. doi: 10.1007/s00464-018-6192-2 URL
[19]	Ou J, DeLany JP, Zhang M, et al. Association between low colonic short-chain fatty acids and high bile acids in high colon cancer risk populations[J]. Nutr Cancer, 2012, 64(1): 34-40. doi: 10.1080/01635581.2012.630164 URL
[20]	Dermadi D, Valo S, Ollila S, et al. Western diet deregulates bile acid homeostasis, cell proliferation, and tumorigenesis in colon[J]. Cancer Res, 2017, 77(12): 3352-3363. doi: 10.1158/0008-5472.CAN-16-2860 pmid: 28416481
[21]	Nakos A, Zezos P, Liratzopoulos N, et al. The significance of histological evidence of bile reflux gastropathy in patients with gastro-esophageal reflux disease[J]. Med Sci Monit, 2009, 15(6):313-318.
[22]	Thomas LA, Veysey MJ, French G, et al. Bile acid metabolism by fresh human colonic contents: a comparison of caecal versus faecal samples[J]. Gut, 2001, 49(6): 835-842. pmid: 11709519

临床特征	对照组（n=882）	AEE组（n=294）	t/χ²	P
年龄（岁）	52.42±8.38	51.71±8.55	0.103	0.951
年龄区间（岁）	19~80	18~78
性别[n（%）]
男性	753（85.4）	251（85.4）
女性	129（14.6）	43（14.6）
BMI（kg/m²）	23.03±0.12	24.06±0.19	4.125	<0.001
BMI区间（kg/m²）	17.14~42.67	16.53~44.12
食管炎等级[n（%）]		294
轻度食管炎		212（72.1）
中重度食管炎		82（27.9）
合并肠道息肉[n（%）]	210（23.8）	101（34.4）	4.142	<0.001
有息肉病理（n）	175	81

变量	单因素Logistic分析			多因素Logistic分析
变量	OR	95% CI	P	OR	95% CI	P
肠道息肉	1.675	1.258~2.230	0.002	1.611	1.207~2.151	0.001
BMI	1.924	1.472~2.526	<0.001	1.087	1.046~1.131	<0.001

指标	对照组（n=882）	AEE组（n=294）	χ²	P
合并结直肠息肉	210（23.9）	101（34.4）	12.603	<0.001
合并不同数量息肉
1	117（55.7）	50（49.5）	3.312	0.069
2	42（20.0）	19（18.8）	0.061	0.805
3	11（5.2）	11（10.9）	3.315	0.069
4	8（3.8）	1（1）	1.056	0.304
>4	32（15.2）	20（19.8）	1.020	0.312
合并不同大小息肉
<5 mm	88（41.9）	34（33.7）	1.943	0.163
5~10 mm	81（38.6）	42（41.6）	0.259	0.611
>10 mm	41（19.5）	25（24.8）	1.115	0.291
有息肉病理	175	81
不同病理类型
炎性息肉	2（1.3）	4（4.9）	2.024	0.155
增生性息肉	64（36.4）	26（32.1）	0.486	0.486
无蒂锯齿状腺瘤/息肉	1（0.5）	0	0	1.000
传统锯齿状息肉	0	0	0	1.000
管状腺瘤	101（57.7）	40（49.4）	1.533	0.213
绒毛状腺瘤	0	0	0	1.000
管状绒毛状腺瘤	7（4.0）	9（11.1）	4.779	0.029
腺癌	0	2（2.5）		0.198
高级别异型增生	0	1（1.2）	0	1.000
低级别异型增生	45（25.7）	14（17.3）	2.219	0.136
高危腺瘤	50（28.6）	34（42.0）	4.512	0.034

指标	轻度食管炎（n=212）	中重度食管炎（n=82）	χ²	P
合并结直肠息肉	71（33.5）	30（36.6）	0.251	0.616
合并不同数量息肉
1	41（57.7）	9（30.0）	6.495	0.011
2	13（18.3）	6（20.0）	0.039	0.843
3	6（8.5）	5（16.7）	0.742	0.389
4	1（1.4）	0	0	1.000
>4	10（14.1）	10（33.3）	4.920	0.027
合并不同大小息肉
<5 mm	27（38.0）	7（23.3）	2.039	0.153
5~10 mm	30（42.3）	12（40.0）	0.044	0.834
>10 mm	14（19.7）	11（36.7）	3.252	0.071
有息肉病理	57	24
不同病理类型
炎症息肉	3（5.3）	1（4.2）	0.000	1.000
增生性息肉	21（36.8）	5（20.8）	1.986	0.159
管状腺瘤	26（45.6）	14（58.3）	1.093	0.296
绒毛状腺瘤	0	0	0.000	1.000
管状绒毛状腺瘤	5（8.8）	4（16.7）	1.093	0.296
腺癌	2（3.5）	0	0.021	0.885
高级别异型增生	1（1.8）	0	0.000	1.000
低级别异型增生	7（12.3）	7（29.2）	2.291	0.130
高危腺瘤	18（31.6）	16（66.7）	8.537	0.003